دورية أكاديمية

Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia

التفاصيل البيبلوغرافية
العنوان: Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia
المؤلفون: Ali, Abraham, García, Elizabeth, Torres-Duque, Carlos A, Rey, Diana, Botero, Laura, Saenz, Stid, Avila, Maria Paula, Mazo, Elizabeth, Londoño, Sergio
المساهمون: Sanofi Colombia
المصدر: Expert Review of Pharmacoeconomics & Outcomes Research ; volume 24, issue 3, page 361-374 ; ISSN 1473-7167 1744-8379
بيانات النشر: Informa UK Limited
سنة النشر: 2024
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1080/14737167.2023.2282668
الإتاحة: https://doi.org/10.1080/14737167.2023.2282668Test
رقم الانضمام: edsbas.E11A5F6F
قاعدة البيانات: BASE